Novel carriers for controlled site specific delivery of anti-inflammatory agents

Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry

Volumn 10, Issue 3, 2011, Pages 166-179

  Gajbhiye, Virendra ^a   Jain, N K ^a  

^a DR H S GOUR UNIVERSITY   (India)

Author keywords

Arthritis; Dendrimers; Inflammation; Liposomes; Microspheres; Nanocarriers; Nanoparticles

Indexed keywords

ACTARIT; ANTIINFLAMMATORY AGENT; CELECOXIB; CHITOSAN; CORTICOSTEROID; CORTICOSTERONE; DEXAMETHASONE; DICLOFENAC; DRUG CARRIER; EUDRAGIT RS; FLURBIPROFEN; GANCICLOVIR; GLUCOCORTICOID; GLYCYRRHIZIC ACID; HYDROCORTISONE; IBUPROFEN; IMMUNOGLOBULIN G; INDOMETACIN; KETOPROFEN; KETOROLAC TROMETAMOL; LIPID NANOPARTICLE; MEFENAMIC ACID; NANOSTRUCTURED LIPID CARRIER; NAPROXEN; PILOCARPINE; PIROXICAM; PREDNISOLONE 21 SODIUM HEMISUCCINATE; ROSE BENGAL; TECHNETIUM 99M; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADJUVANT ARTHRITIS; ANTIINFLAMMATORY ACTIVITY; AREA UNDER THE CURVE; COMPARATIVE STUDY; CONJUGATION; CONTROLLED DRUG RELEASE; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; DRUG SAFETY; DRUG TARGETING; DRUG UPTAKE; HUMAN; HYDROGEL; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PARTICLE SIZE; PRECIPITATION; REVIEW; SUSPENSION; SUSTAINED DRUG RELEASE; SYSTEMIC DISEASE;

EID: 79960633192     PISSN: 18715230     EISSN: 1875614X     Source Type: Journal    
DOI: 10.2174/1871523011109030166     Document Type: Review

References (93)

1. Marie, R.G. Epidemiology of nonsteroidal anti-inflammatory drugassociated gastrointestinal injury. Am. J. Med., 1998, 104, 23S.
2. Chi, S.C.; Jun, H.W. Anti-inflammatory activity of ketoprofen gel on carrageenan-induced paw edema in rats. J. Pharm. Sci., 1990, 79, 974-977.
3. Lin, S.Z.; Wouessidjewe, D.; Poelman, M.C.; Duchone, D. In vivo evaluation of indomethacin: cyclodextrin complexes: Gastrointestinal tolerance and dermal anti-inflammatory activity. Int. J. Pharm., 1994, 106, 63-67.
4. Timothy, A.C. Nonsteroidal anti-inflammatory drugs, apoptosis, and colon cancer chemoprevention. Lancet Oncol., 2002, 3, 166-174.
5. Gabriel, S.E.; Jaakkimainnen, R.L.; Bombarier, C. Risk for serious gastrointestinal complications related to use of nonsteroidal antiinflammatory drugs: a meta-analysis. Ann. Intern. Med., 1991, 115, 787-796.
6. Denis, M.M. Comparative toxicity of nonsteroidal antiinflammatory drugs. Am. J. Med., 1999, 107, 37S.
7. Marie, R.G. Nonsteroidal anti-inflammatory drugs: Practical and theoretical considerations in their selection. Am. J. Med., 1996, 100, 31S.
8. Jacobs, J.; Golstein, A.G.; Kelly, M.E.; Bloom, B.S. NSAID dosing schedule and compliance. Drug Intell. Clin. Pharm., 1988, 22, 726-727.
9. Woo, B.W.; Jiang, G.; Jo, Y.W.; DeLuca, P.P. Preparation and characterization of a composite PLGA and poly (acryloyl hydroxyethyl starch) microsphere system for protein delivery. Pharm. Res., 2001, 18, 1600-1606.
10. Schrier, J.A.; DeLuca, P.P. Recombinant human bone morphogenetic protein-2 binding and incorporation in PLGA microsphere delivery. Pharm. Dev. Technol., 1999, 4, 611-621.
11. Okada, H.Y.; Heya, I.T.; Ueno, H.; Ogawa, Y.; Toguchi, H. Pharmacokinetics of once-a-month injectable microspheres of Leuprolide Acetate. Pharm. Res., 1991, 8, 787-791.
12. Thakkar, H.; Sharma, R.K.; Mishra, A.K.; Chuttani, K.; Murthy, R.S.R. Celecoxib Incorporated Chitosan Microspheres: In Vitro and In Vivo Evaluation. J. Drug Target., 2004, 12, 549-557.
13. Thakkar, H.; Sharma, R.K.; Mishra, A.K.; Chuttani, K.; Murthy, R.S.R. Albumin Microspheres as Carriers for the Antiarthritic Drug Celecoxib. AAPS PharmSciTech., 2005, 6, 65-73.
14. Mathew, S.T.; Devi, S.G., Sandhya, K.V. Formulation and Evaluation of Ketorolac Tromethamine-loaded Albumin Microspheres for Potential Intramuscular Administration. AAPS PharmSciTech., 2007, 8,14.
15. Coimbra, P.A.; De-Sousa, H.C.; Gil, M.H. Preparation and characterization of flurbiprofen-loaded poly(3-hydroxybutyrate-co-3- hydroxyvalerate) microspheres. J. Microencap., 2008, 25, 170-178.
16. Ranjha, N.M.; Khan, I.U.; Naseem, S., Encapsulation and characterization of flurbiprofen loaded poly(?-caprolactone)- poly(vinylpyrrolidone) blend micropheres by solvent evaporation method. J. Sol-Gel Sci Tech., 2009, 50, 281-289.
17. Lu, Y.; Zhang, G.; Sun D.; Zhong, Y., Preparation and evaluation of biodegradable flubiprofen gelatin micro-spheres for intraarticular administration. J. Microencap., 2007, 24, 515-524.
18. Hausberger, G.; DeLuca, P.P. Characterization of biodegradable poly (D, L-lactide-co-glycolide) polymers and microspheres. J. Pharm. Biomed. Anal., 1995, 13, 747-760.
19. Puebla, P.; Pastoriza, P.; Barcia, E.; Fernndez-Carballido, A. PEGderivative effectively modifies the characteristics of indomethacin-PLGA microspheres destined to intra-articular administration. J. Microencap., 2005, 22, 793-808.
20. Bozdag, S.; Çalis-Kas, H.S.; Ercan, M.T.; Peksoy, I.; Hincal, A.A. In vitro evaluation and intra-articular administration of biodegradable microspheres containing naproxen sodium. J. Microencap., 2001, 18, 443-456.
21. Hickey, T.; Kreutzer, D.; Burges, D.J.; Moussy, F. Dexamethasone/ PLGA microspheres for continuous delivery of an antiinflammatory drug for implantable medical devices. Biomaterials, 2002, 23,1649-1656.
22. Wassef, M.; Pelage, J.P.; Velzenberger, E.; Namur, J.; Schwartz-Cornil, I.; Taylor, R.R.; Lewis, A.L.; Laurent, A. Antiinflammatory effect of ibuprofen-loaded embolization beads in sheep uterus. J. Biomed. Mater. Res. Part B: Applied Biomaterials, 2007, 83, 63-73.
23. Chandy, A.; Rai, S.; Manigauha, A.; Sahu, S. Entric-Coated Pectin Microspheres of Indomethacin for Targeting Inflammation in Lower Gastro intestinal tract. Research J. Pharma. Dosage Forms and Tech., 2009, 1, 29-32.
24. Deore, B.V.; Mahajan, H.S.; Deore, U.V. Development and characterization of sustained release microspheres by quasi emulsion solvent diffusion method. Int. J. ChemTech. Research, 2009, 1, 634-642.
25. Veronese, F.M.; Marsilio, F.; Caliceti, P.; Filippis, P.D.; Giunchedi, P.; Lora, S. Polyorganophosphazene microspheres for drug release: polymer synthesis, microsphere preparation, in vitro and in vivo naproxen release. J. Control. Rel., 1998, 52, 227-237.
26. Gonçalves, V.L.; Laranjeira, M.C.M.; Favere, V.T. Effect of Crosslinking Agents on Chitosan Microspheres in Controlled Release of Diclofenac Sodium. Polímeros: Ciencia e Tecnologia., 2005, 15, 6-12.
27. Saravanan, M.; Bhaskar, K.; Maharajan, G.; Pillai, K.S. Ultrasonically controlled release and targeted delivery of diclofenac sodium via gelatin magnetic microspheres. Int. J. Pharma., 2004, 283, 71-82.
28. Lalla, J.K.; Ahuja, P.L. Drug targeting using non-magnetic and magnetic albumin-globulin mix microspheres of mefenamic acid. J. Microencapsul., 1991, 8, 37-52.
29. Wu, Y.; Guo, J.; Yang, W.; Wang, C.; Shoukuan, Fu. Preparation and characterization of chitosan-poly(acrylic acid) polymer magnetic microspheres. Polymer, 2006, 47, 5287-5294.
30. Butoescu, N.; Jordan, O.; Burdet, P.; Stadelmann, P.; Petri-Fink, A.; Hofmann, H.; Doelker, E. Dexamethasone-containing biodegradable superparamagnetic microparticles for intra-articular administration: Physicochemical and magnetic properties, in vitro and in vivo drug release. Eur. J. Pharm. Biopharm., 2009, 72, 529-538.
31. N. Butoescu, C.A. Seemayer, M. Foti, O. Jordan, E. Doelker, Dexamethasone containing PLGA superparamagnetic microparticles as carriers for the local treatment of arthritis. Biomaterials, 2009, 30, 1772-1780.
32. Muthu, M.S.; Rawat, M.K.; Mishra, M.; Singh, S. PLGA nanoparticle formulations of risperidone: preparation and neuropharmacological evaluation. Nanomedicine: NBM, 2009, 5, 323-333.
33. Kavanagh, O.V.; Early, B.; Murray, M.; Foster, C.J.; Adair, B.M. Antigen specific IgA and IgG responses in calves inoculated intranasally with ovalbumin encapsulated in poly (D, L-lactide-coglycolide) microspheres. Vaccine, 2003, 21, 4472-4480.
34. Jiang, W.; Gupta, R.K.; Deshpande, M.C. Schwendeman, S.P. Biodegradable poly (lactic-co-glycolic acid) microparticles for injectable delivery of vaccine antigens. Adv. Drug. Del. Rev., 2005, 57, 391-410.
35. Wikingsson, L.; Sjoholm, I. Polyacryl starch microparticles as adjuvant in oral immunization, inducing mucosal and systemic immune responses in mice. Vaccine, 2002, 20, 3353-3363.
36. McNeela, E.; O'Connor, D.; Jabbal-Gill, I.; Illum, L.; Davis, S.S.; Pizza, M. A mucosal vaccine against diphtheria: formulation of cross reacting material (CRM (197) of diphtheria toxin with chitosan enhances local and systemic and TH2 responses following nasal delivery. Vaccine, 2000, 19, 1188-1198.
37. Van der Lubben, I.M; Kersten, G.; Fretz, M.M.; Beuvery, C.; Verhoef, J.C.; Junginger, H.E. Chitosan microparticles for mucosal vaccination against diphtheria: oral and nasal efficacy studies in mice. Vaccine, 2003, 21,1400-1408.
38. Kersten, G.; Hirshberg, H. Antigen delivery systems. Expert Rev. Vaccines, 2004, 3, 453-462.
39. Zimmer, A.K.; Chetoni, P.; Saettone, M.F.; Zerbe, H.; Kreuter, J. Evaluation of pilocarpine loaded albumin particles as controlled drug delivery systems for the eye. II. Co-administration with bioadhesive and viscous polymers. J. Control. Rel., 1995, 33, 31-46.
40. Zimmer, A.K.; Maincent, P.; Thouvenot, P.; Kreuter, J. Hydrocortisone delivery to healthy and inflamed eyes using a micellar polysorbate 80 solution or albumin nanoparticles. Int. J. Pharm., 1994, 110, 211-222.
41. Pignatelloa, R.; Bucolo, C.; Ferrara, P.; Maltese, A.; Puleo, A.; Puglisi, G. Eudragit RS100 nanosuspensions for the ophthalmic controlled delivery of ibuprofen. Euro. J. Pharm. Sci., 2002, 16, 53-61.
42. Pignatellob, R.; Bucolo, C.; Spedalieri, G.; Maltese, A.; Puglisi, G. Flurbiprofen-loaded acrylate polymer nanosuspensions for ophthalmic application. Biomaterials, 2002, 23, 3247-3255.
43. Lin, W.; Garnett, M.C.; Davis, S.S.; Schacht, E.; Ferruti, P.; Illum, L. Preparation and characterisation of rose Bengal-loaded surfacemodified albumin nanoparticles. J. Control Rel., 2001, 71, 117-126.
44. Merodio, M.; Irache, J.M.; Valamanesh, F.; Mirshahi, M. Ocular disposition and tolerance of ganciclovir-loaded albumin nanoparticles after intravitreal injection in rats. Biomaterials, 2002, 23, 1587-1594.
45. Das, S.; Banerjee, R.; Bellare, J. Aspirin Loaded Albumin Nanoparticles by Coacervation: Implications in Drug Delivery, Trends Biomater. Artif. Organs, 2005, 18, 178-186.
46. Sashmal, S.; Mukherjee, S.; Ray, S.; Thakur, R.S.; Ghosh, L.K.; Gupta, B.K. Design And Optimization of NSAIDs Loaded Nanoparticles. Pak. J. Pharm. Sci., 2007, 20, 157-162.
47. Bhaskar, K.; Anbu, J.; Ravichandiran, V.; Venkateswarlu, V.; Rao, Y.M. Lipid nanoparticles for transdermal delivery of flurbiprofen: formulation, in vitro, ex vivo and in vivo studies. Lipids Health Dis., 2009, 8, 1-15.
48. Jain, P.; Mishra, A.; Yadav, S.K.; Patil, U.K.; Baghel, U.S. Formulation Development and Characterization of Solid Lipid Nanoparticles Containing Nimesulide. Int. J. Drug Delivery Tech., 2009, 1, 24-27.
49. Ye, J.; Wang, Q.; Zhoua, X.; Zhang, N. Injectable actarit-loaded solid lipid nanoparticles as passive targeting therapeutic agents for rheumatoid arthritis. Int. J. Pharm., 2008, 352, 273-279.
50. Radwan, M.A.; Aboul-Enein, H.Y. In vitro release and stereoselective disposition of flurbiprofen loaded to poly(D,Llactide-co-glycolide) nanoparticles in rats. Chirality, 2003, 16, 119-125.
51. Liu, M.; Dong, J.; Yang, Y.; Yang, X.; Xu, H. Anti-inflammatory effects of triptolide loaded poly(d,l-lactic acid) nanoparticles on adjuvant-induced arthritis in rats. J. Ethnopharm., 2005, 97, 219-225.
52. Lu, X.; Howard, M.D.; Mazik, M.; Eldridge, J.; Rinehart, J.J.; Jay, M.; Leggas, M. Nanoparticles Containing Anti-inflammatory Agents as Chemotherapy Adjuvants: Optimization and In Vitro Characterization. AAPS J., 2008, 10, 133-140.
53. Moulari, B.; Pertuit, D.; Pellequer, Y.; Lamprecht, A. The targeting of surface modified silica nanoparticles to inflamed tissue in experimental colitis. Biomaterials, 2008, 29, 4554-4560.
54. Kemp, M.M.; Kumar, A.; Mousa, S.; Park, T.J.; Ajayan, P.; Kubotera, N.; Mousa, S.A.; Linhardt, R.J., Synthesis of Gold and Silver Nanoparticles Stabilized with Glycosaminoglycans Having Distinctive Biological Activities. Biomacromole, 2009, 10, 589-595.
55. Timko, M.; Koneracka, M.; Tomasovicova, N.; Kopcansky, P.; Zavisova, V. Magnetite polymer nanospheres loaded by Indomethacin for anti-inflammatory therapy. J. Magnet Mag. Mater., 2006, 300, 191-194.
56. Zavisova, V.; Koneracka, M.; Strbaka, O.; Tomasovicova, N.; Kopcansky, P.; Timko, M.; Vavra, I. Encapsulation of indomethacin in magnetic biodegradable polymer nanoparticles. J. Magnet Mag. Mater., 2007, 311, 379-382.
57. Gregoriadis, G. The liposome drug-carrier concept: its development and future. In: Gregoriadis, G.; Allison, A.C. (Eds.), Liposomes in Biological Systems. Wiley, New York, 1980, 25-86.
58. Woodley, J.F. Liposomes for oral administration of drugs. Crit. Rev. Ther. Drug Carrier Syst., 1985, 2, 1-18.
59. Rogers, J.A.; Anderson, K.E. The potential of liposomes in oral drug delivery. Crit. Rev. Ther. Drug Carrier Syst., 1998, 15, 421-480.
60. Allison, S.D. Liposomal drug delivery. J. Infus. Nurs., 2007, 30, 89-95.
61. Nii, T.; Ishii, F. Encapsulation efficiency of water-soluble and insoluble drugs in liposomes prepared by the microencapsulation vesicle method. Int. J Pharm., 2005, 298,198-205.
62. Srinath, P.; Chary, M.G.; Vyas, S.P.; Diwan, P.V. Long-circulating liposomes of indomethacin in arthritic rats-a biodisposition study. Pharmaceutica Acta Helvetiae, 2000, 74, 399-404.
63. Mizushima, Y.; Wada, Y.; Etoh, Y.; Watanabe, K. Anti-inflammatory effects of indomethacin ester incorporated into a lipid microsphere. J. Pharm. Pharmacol., 1983, 35, 398-399.
64. Metselaar, J.M.; van den Berg, W.B.; Holthuysen, A.E. Wauben, M.H. Storm, G.; van Lent, P.L. Liposomal targeting of glucocorticoids to synovial lining cells strongly increases therapeutic benefit in collagen type II arthritis. Ann. Rheum. Dis., 2004, 63, 348-353.
65. Metselaar, J.M.; Wauben, M.H.; Boerman, O.C.; van Lent P.L.; Storm, G. Long-circulating liposomes for i.v. targeted delivery of glucocorticoids in arthritis. Cell. Mol. Biol. Lett., 2002, 7, 291-292.
66. Elron-Gross, I.; Glucksam, Y.; Margalit, R. Liposomal dexamethasone-diclofenac combinations for local osteoarthritis treatment. Int. J. Pharm., 2009, 376, 84-91.
67. [Desu, H.R.; Wood, G.C.; Divi, M.K.; Kannan, V.; Bhattacharjee, H.; Thoma, L.A. Development and Lyophilization of Methylprednisolone Entrapped RGD-peptide Conjugated Liposomes. 2008, aapspharmaceutica.com/ExpoAAPS08
68. Schleining, J.A.; Mcclure, S.R.; Evans, R.B.; Hyde, W.G.; Wulf, L.W.; Kind, A.J. Liposome-based diclofenac for the treatment of inflammation in an acute synovitis model in horses. J. Veterinary Pharmacol. Therapeut., 2008, 31, 554-561.
69. Schwartz, G.; Pashko, L.L. Suppression of 12-O-tetradecanoylphorbol-13-acetate-induced epidermal hyperplasia and inflammation by the dehydroepiandrosterone analog 16a-fuoro-5- androsten-17-one and its reversal by NADPH liposomes. Cancer Lett, 2001, 168, 7-14.
70. Aulenta, F.; Hayes, W.; Rannard, S. Dendrimers: a new class of nanoscopic containers and delivery devices. Eur. Polymer J., 2003, 39, 1741-1771.
71. Gajbhiye, V.; Kumar, P.V.; Tekade, R.K.; Jain, N.K. Pharmaceutical & biomedical potential of PEGylated dendrimers. Curr. Pharm. Design, 2007, 13, 425-439.
72. Heegaard, P.M.; Boas, U. Dendrimer based anti-infective and antiinflammatory drugs. Recent Pat. Antiinfect. Drug Discov., 2006, 1, 331-51.
73. Gajbhiye, V.; Kumar, P.V.; Tekade, R.K.; Jain, N.K. Therapeutic Dendrimers: A Systematic Review. J. Pharmacy Pharmacol., 2009, 61, 989-1003.
74. Gajbhiye, V.; Vijayarajkumar, P.V.; sharma, A.; Agrawal, A.; Asthana, A.; Jain, N.K. Dendrimer mediated transdermal & oral delivery of bioactives. Indian J. Pharm. Sciences, 2008, 70, 431-439.
75. Wang, B.; Raghavendra, N.; Roberto, R.; Sujatha, K.; Rangaramanujam, K. Anti-inflammatory and anti-oxidant activity of anionic dendrimer-N-acetyl cysteine conjugates in activated microglial cells. Int. J. Pharm., 2009, 377, 159-168.
76. Yiyun, C.; Na, M.; Tongwen, X.; Rongqiang, F. Xueyuan, W.; Xiaomin, W.; Longping, W. Transdermal delivery of nonsteroidal anti-inflammatory drugs mediated by polyamidoamine (PAMAM) dendrimers. J. Pharm. Sci., 2007, 96, 595-602.
77. Kolhe, P.; Khandare, J. Pillai, O.; Kannan, S.; Lieh-Lai, M.; Kannan, R.M. Preparation, cellular transport, and activity of polyamidoamine-based dendritic nanodevices with a high drug payload. Biomaterials, 2006, 27, 660-669.
78. Na, M.; Yiyun, C.; Tongwen, X.; Yang, D.; Xiaomin, W.; Zhenwei, L.; Zhichao. C.; Guanyi, H.; Yunyu, S.; Longping, W. Dendrimers as potential drug carriers. Part II. Prolonged delivery of ketoprofen by in vitro and in vivo studies. Eur. J. Med. Chem., 2006, 41, 670-674.
79. Chandrasekar, D.; Sistla, R.; Ahmad, F.J.; Khar, R.K.; Diwan, P.V. The development of folate-PAMAM dendrimer conjugates for targeted delivery of anti-arthritic drugs and their pharmacokinetics and biodistribution in arthritic rats. Biomaterials, 2007, 28, 504-512.
80. Chauhan, A.S.; Sridevi, S.; Chalasani, K.B.; Jain, A.K.; Jain, S.K.; Jain, N.K.; Diwan, P.V. Dendrimer-mediated transdermal delivery: enhanced bioavailability of indomethacin. J. Control. Rel., 2003, 9, 335-343.
81. Chauhan, A.; Jain, N.K. Composition and complexes containing a macromolecular polymer as potential anti-inflammatory agents. US Patent 20030180250 A1, 2003.
82. Chauhan, A.S.; Jain, N.K. Macromolecular compound as potential anti-inflammatory agents. WO/2003/080121, 2003.
83. Chauhan, A.S.; Jain, N.K.; Diwan, P.V.; Khopade, A.J. Solubility enhancement of indomethacin with poly(amidoamine) dendrimers and targeting to inflammatory regions of arthritic rats. J. Drug Target., 2004,12, 575-583.
84. Asthana, A.; Chauhan, A.S.; Diwan, P.V.; Jain, N.K. Poly(amidoamine) (PAMAM) Dendritic Nanostructures for Controlled Site-specific Delivery of Acidic Anti-inflammatory Active Ingredient. AAPS PharmSciTech., 2005, 6, E536-E542.
85. Gajbhiye, V.; Kumar, P.V.; Sharma, A.; Jain, N.K. PEGylated PPI dendritic architectures for sustained delivery of anti-inflammatory agent. Curr. Nanosci., 2008, 4, 267-277.
86. Prajapati, R.; Tekade, R.K.; Gupta, U.; Gajbhiye, V.; Jain, N.K. Dendimer-mediated solubilization, formulation development and in vitro-in vivo assessment of piroxicam. Mole. Pharm., 2009, 6, 940-950.
87. Lewis, D.A.; Alpar, H.O. Therapeutic possibilities of drugs encapsulated in erythrocytes. Int. J. Pharm., 1984, 22, 137-146.
88. Jain, S.; Jain, N.K. Engineered erythrocytes as a drug delivery system. Indian J. Pharm. Sci., 1997, 59, 275-281.
89. Pitt, E.; Lewis, D.A.; Offord, R. The use of corticosteroids encapsulated in erythrocytes in the treatment of adjuvant induced arthritis in the rat. Biochem. Pharmacol., 1983, 132, 3355-3358.
90. Jenner, D.J.; Lewis, D.A.; Pitt, E.; Offord, R.A. The effect of the intravenous administration of corticosteroids encapsulated in intact erythrocytes on adjuvant arthritis in the rat. Br. J. Pharmacol., 1981, 73, 212-213.
91. Ogiso, T.; Iwaki, M.; Ohtori, A. Encapsulation of dexamethasone in rabbit erythrocytes, the disposition in circulation and antiinflammatory effect. J. Pharmacobio-dyn., 1985, 8, 1032-1040.
92. Rossi, L.; Castro, M.; D'Orio, F.; Damonte, G.; Serafini, S.; Bigi, L.; Panzani, I.; Novelli, G.; Dallapiccola, B.; Panunzi, S.; Di Carlo, P.; Bella, S.; Magnania, M. Low doses of dexamethasone constantly delivered by autologous erythrocytes slow the progression of lung disease in cystic fibrosis patients. Blood Cells Mole. Dis., 2004, 33, 57-63.
93. Jain, S.K.; Vyas, S.P. Magnetically responsive diclofenac sodiumloaded erythrocytes: preparation and in vitro characterization. J. Microencapsul., 1994, 11, 141-151.